drugset

drugset / Trial / NCT06481098

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

NCT06481098 ↗

Phase 1 Completed 74 enrolled Hanmi Pharmaceutical Company Limited

RandomizedSequentialTriple-blindTreatment

Summary

This Study is a Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15275 in Healthy and Obese Subjects.

Timeline

Start: 2024-05-28
Primary completion: 2025-05-02
Completion: 2025-05-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HM15275	Unknown	—	Subcutaneous

Indications